FDA Regulatory Policy Information Relating to Compounding found at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm166743.htm

Date Issued	Type	Title	Additional Information
10/26/2015	Final Guidance	Pharmacy Compounding of HumanDrug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance (PDF - 86KB)	N/A
10/26/2015	Draft Guidance	Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (PDF - 105KB)	Notice of Availability
10/26/2015	Draft Guidance	Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (PDF - 126KB)	Notice of Availability
10/26/2015	Request for Nominations	Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket	N/A
10/26/2015	Request for Nominations	Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket	N/A
10/8/2015	Final Guidance	Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act	Notice of Availability
8/12/2015	Final Guidance	Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act	Notice of Availability
8/3/2015	FR Notice	Outsourcing Facility Fee Rates for Fiscal Year 2016	N/A
3/6/2015	Public Docket	Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket	N/A
2/13/2015	Draft MOU	Draft Memorandum of Understanding Addressting Certain Distributions of Compounded Human Drug Products Between the State of [insert STATE] and the U.S. Food and Drug Administration	Notice of Availability
2/13/2015	Draft Guidance	Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities	Notice of Availability
2/13/2015	Draft Guidance	Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application	Notice of Availability
11/24/2014	Final Guidance	Fees for Human Drug Compounding Outsourcing Facilities Under the FD&C Act	Notice of Availability
11/24/2014	Final Guidance	Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act	Notice of Availability
11/24/2014	Revised Draft Guidance	Electronic Product Reporting for Human Drug Compounding Outsourcing Facilities	Notice of Availability
7/2/2014	Request for Nominations	Bulk Drug Substances that May be Used to Compound Drug Products in Accordance with Section 503A of the Federal Food, Drug, and Cosmetic Act; Revised Request for Nominations	N/A
7/2/2014	Request for Nominations	Bulk Drug Substances That May Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act, Concerning Outsourcing Facilities; Revised Request for Nominations	N/A
7/2/2014	Proposed Rule	Additions and Modifications to the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness	N/A
7/2/2014	Draft Guidance	Current Good Manufacturing Practice-Interim Guidance for Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug and Cosmetic Act	Notice of Availability
12/4/2013	Request for Nominations	List of Bulk Drug Substances That May Be Used in Pharmacy Compounding; Bulk Drug Substances That May Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Request for Nominations	N/A
12/4/2013	Request for Nominations	Bulk Drug Substances That May Be Used to Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act Concerning Outsourcing Facilities	N/A
12/4/2013	Request for Nominations	Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act	N/A